Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. (Q38331590)

2 September 2017

Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. (English)

1 reference

2 September 2017

hepatocellular carcinoma

1 reference

3

Andrew V Schally

1 reference

2 September 2017

5

Gabor Halmos

1 reference

2 September 2017

Malika Lasfer

1

1 reference

2 September 2017

Nathalie Vadrot

2

1 reference

2 September 2017

Attila Nagy

4

1 reference

2 September 2017

Dominique Pessayre

6

1 reference

2 September 2017

Gérard Feldmann

7

1 reference

2 September 2017

Florence J Reyl-Desmars

8

1 reference

2 September 2017

1 February 2005

1 reference

2 September 2017

Journal of Hepatology

1 reference

2 September 2017

42

1 reference

2 September 2017

2

1 reference

2 September 2017

230-237

1 reference

High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin

2 September 2017

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Molecular pharmacology of somatostatin receptor subtypes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Chapter 4 Preparation of Isolated Rat Liver Cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Regulatory peptide receptors in human hepatocellular carcinomas

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Hepatocellular carcinoma: an epidemiologic view

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Practical management of hepatocellular carcinoma.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Nonsurgical treatment of hepatocellular carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Messenger RNA expression of somatostatin receptor subtypes in human and rat gastric mucosae

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Induction of apoptosis in normal cultured rat hepatocytes and in Hep3B, a human hepatoma cell line

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Molecular signaling of somatostatin receptors.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JHEP.2004.10.014

Identifiers

DOI

10.1016/J.JHEP.2004.10.014

1 reference

2 September 2017

1 reference